✓ Translated by DotMD AI Clinical Council Source: Diabetes, obesity & metabolism • Phase III Randomized Trial
Verify Primary Source: NIH PubMed PMID #39996356 ↗

Phase III Randomized Trial: Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight (N = 160)

Original Paper Title: “Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight”

Elena Rostova (AI Quant) Rigor Score
88 / 100
Sample Size (Participants)
N = 160
Evidence Classification
Phase III Randomized Trial
Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways
  • In participants with obesity or overweight from the SURMOUNT-1 trial, tirzepatide treatment significantly reduced body weight, fat mass and lean mass compared with placebo, while in post hoc analyses, the proportion of body weight lost as fat or lean mass was relatively consistent including in clinically relevant subgroups.
  • Study Design & Sample: Phase III Randomized Trial published in Diabetes, obesity & metabolism (N = 160 human participants).
  • Biostatistical Rigor Score: 88/100 audited by Elena Rostova (AI Biostatistician & openFDA Quant).

What the Study Found (In Plain English)

Published in Diabetes, obesity & metabolism (2025), this phase iii randomized trial evaluating 160 human participants investigated: We assessed changes in body composition following tirzepatide treatment in a substudy of participants with obesity or overweight from the SURMOUNT-1 trial, overall and post hoc in clinically relevant subgroups. Key clinical takeaway: In participants with obesity or overweight from the SURMOUNT-1 trial, tirzepatide treatment significantly reduced body weight, fat mass and lean mass compared with placebo, while in post hoc analyses, the proportion of body weight lost as fat or lean mass was relatively consistent including in clinically...

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Primary Endpoint & Quantitative Summary (Diabetes, obesity & metabolism, 2025-05-15; N = 160; Rigor 88/100): In participants with obesity or overweight from the SURMOUNT-1 trial, tirzepatide treatment significantly reduced body weight, fat mass and lean mass compared with placebo, while in post hoc analyses, the proportion of body weight lost as fat or lean mass was relatively consistent including in clinically relevant subgroups.

Study Limitations & Caveats Before You Act

Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.

Related DotMD Clinical Hubs & Price Ledgers

Rx: tirzepatide → Condition: dietary-fiber → Condition: metabolic-syndrome-weight-loss →
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 39996356: Phase III Randomized Trial: Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight (N = 160)

3 of 3 Free Questions Remaining